Bayer announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved finerenone (Kerendia), a non-steroidal, selective mineralocorticoid receptor antagonist (nsMRA), for the treatment of adult patients… read more.
Veteran male athletes who have spent years training at high intensity may be at greater risk of serious heart problems while exercising, new University of Leeds research shows…. read more.
A new study from UCLA Health shows that a cardiovascular risk score already used routinely in primary care can predict who will develop serious eye diseases years later…. read more.
Patients who start their blood pressure treatment with ARB drugs continue with the same medicine to a greater extent than patients who start out with other drugs. Choosing… read more.
A new Finnish study shows that adults who remain physically active throughout adulthood have a markedly lower prevalence of metabolic syndrome at the age of 61 than those… read more.
Cytokinetics, Incorporated announced that Myqorzo (aficamten) has been approved by the China National Medical Products Administration (NMPA) for the treatment of adults with New York Heart Association (NYHA)… read more.
Cuffless devices to measure blood pressure, such as smartwatches, rings, patches and fingertip monitors, show great promise as alternatives to traditional arm-cuff monitors, however, they are not yet… read more.
A new AI model could help radiologists identify brain abnormalities in MRI scans for all conditions including stroke, multiple sclerosis and brain tumours. The study, led by researchers at King’s… read more.
Clinicians may fail to recognize common side effects of drugs like gabapentin — which are frequently prescribed for nerve pain — leading them to prescribe unnecessary medications that… read more.
Some blood pressure medications can make the skin extra prone to sunburn. A registry study from Lund University in Sweden shows a possible increased risk of basal cell… read more.
Edwards Lifesciences announced data demonstrating successful patient outcomes supporting its portfolio of mitral and tricuspid therapies. One-year data from the ENCIRCLE single-arm pivotal trial achieved all primary and… read more.
Amarin Corporation highlighted a new post hoc analysis of aspirin use in REDUCE-IT® reinforcing that icosapent ethyl significantly reduced cardiovascular (CV) events in high-risk patients. These findings highlight the… read more.
Advertisment
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
